第2个回答 2019-08-14
我也是查这个问题,翻到文献,算是对“hsf155752”说法的来源补充。
《Pharmacodynamic biomarkers for molecular cancer therapeutics.》中的原话:
Whereas PK endpoints are concerned with “what the body does to the drug,” PD biomarkers focus on “what the drug does to the body”.
作者引用的文献:
Workman, P. (2002). Challenges of PK/PD measurements in modern drug development. Eur.J. Cancer 38, 2189–2193.
Workman, P. (2003a). How much gets there and what does it do?: The need for better
pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr. Pharm. Des. 9, 891–902.